Treatment of chronic hepatitis due to hepatitis B and hepatitis delta virus coinfection

被引：14

作者：

Brancaccio, Giuseppina ^{[1
]}

Gaeta, Giovanni B. ^{[2
]}

机构：

[1] Univ Padua, Dept Mol Med, Infect Dis, Padua, Italy

[2] Campania Univ, Dept Mental & Phys Hlth, Infect Dis, Naples, Italy

来源：

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS | 2019年 / 54卷 / 06期

关键词：

Hepatitis delta virus; Peg-IFN; Prenylation inhibitor; Entry inhibitor; HBsAg release blocker; IFN-lambda; PEGYLATED INTERFERON ALPHA-2A; PEG-INTERFERON; VANISHING DISEASE; CLINICAL-TRIAL; MYRCLUDEX B; OPEN-LABEL; EFFICACY; THERAPY; INFECTION; RNA;

D O I：

10.1016/j.ijantimicag.2019.09.012

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

An estimated 20-40 million individuals worldwide are infected with hepatitis delta virus (HDV), mostly with rapidly evolving liver disease. Therapy of chronic HDV infection remains an unmet need. To date, only interferon (IFN)-based therapy is recommended for HDV infection and response rates are unsatisfactory; in addition, many patients are intolerant to or ineligible for IFN treatment. In recent years, innovative approaches have been in development, including the following: targeting virus entry into hepatocytes; inhibition of the host enzyme farnesyltransferase by prenylation inhibitors, leading to inhibition of complete virion formation and release; blockade of hepatitis B surface antigen (HBsAg) secretion, inhibiting virus release; and IFN-lambda, which causes fewer adverse effects than IFN-alfa. Clinical trials are ongoing with encouraging preliminary results. (C) 2019 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.

引用

页码：697 / 701

页数：5

共 64 条

[11] Efficacy of interferon α-2b and lamivudine combination treatment in comparison to interferon α-2b alone in chronic delta hepatitis:: A randomized trial [J].

Canbakan, B ;

Senturk, H ;

Tabak, F ;

Akdogan, M ;

Tahan, V ;

Mert, A ;

Sut, N ;

Ozaras, R ;

Midilli, K ;

Ozbay, G .

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 (04) :657-663

[12] Efficacy of peginterferon alpha-2b in chronic hepatitis delta:: Relevance of quantitative RT-PCR for follow-up [J].

Castelnau, Corinne ;

Le Gal, Frederic ;

Ripault, Marie-Pierre ;

Gordien, Emmanuel ;

Martinot-Peignoux, Michelle ;

Boyer, Nathalie ;

Pham, Bach-Nga ;

Maylin, Sarah ;

Bedossa, Pierre ;

Deny, Paul ;

Marcellin, Patrick ;

Gault, Elyanne .

HEPATOLOGY, 2006, 44 (03) :728-735

[13] Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis [J].

Chen, Hai-Yan ;

Shen, Dan-Ting ;

Ji, Dong-Ze ;

Han, Pei-Chun ;

Zhang, Wei-Ming ;

Ma, Jian-Feng ;

Chen, Wen-Sen ;

Goyal, Hemant ;

Pan, Shiyang ;

Xu, Hua-Guo .

GUT, 2019, 68 (03) :512-521

[14] The increasing prevalence of hepatitis delta virus (HDV) infection in South London [J].

Cross, Timothy J. S. ;

Rizzi, Paolo ;

Horner, Mary ;

Jolly, Anita ;

Hussain, Munther J. ;

Smith, Heather M. ;

Vergani, Diego ;

Harrison, Phillip M. .

JOURNAL OF MEDICAL VIROLOGY, 2008, 80 (02) :277-282

[15] Treatment of chronic hepatitis delta with pegylated interferon-α2b [J].

Erhardt, Andreas ;

Gerlich, Wolfram ;

Starke, Christine ;

Wend, Ulrike ;

Donner, Andreas ;

Sagir, Abdurrahman ;

Heintges, Tobias ;

Haeussinger, Dieter .

LIVER INTERNATIONAL, 2006, 26 (07) :805-810

[16] EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection [J].

Lampertico P. ;

Agarwal K. ;

Berg T. ;

Buti M. ;

Janssen H.L.A. ;

Papatheodoridis G. ;

Zoulim F. ;

Tacke F. .

JOURNAL OF HEPATOLOGY, 2017, 67 (02) :370-398

[17] Long-term benefit of interferon a therapy of chronic hepatitis D: Regression of advanced hepatic fibrosis [J].

Farci, P ;

Roskams, T ;

Chessa, L ;

Peddis, G ;

Mazzoleni, AP ;

Scioscia, R ;

Serra, G ;

Lai, ME ;

Loy, M ;

Caruso, L ;

Desmet, V ;

Purcell, RH ;

Balestrieri, A .

GASTROENTEROLOGY, 2004, 126 (07) :1740-1749

[18] Chronic hepatitis D: A vanishing disease? An Italian multicenter study [J].

Gaeta, GB ;

Stroffolini, T ;

Chiaramonte, M ;

Ascione, T ;

Stornaiuolo, G ;

Lobello, S ;

Sagnelli, E ;

Brunetto, MR ;

Rizzetto, M .

HEPATOLOGY, 2000, 32 (04) :824-827

[19] Hepatitis delta in Europe: Vanishing or refreshing? [J].

Gaeta, Gvanni B. ;

Stroffolini, Tommaso ;

Smedile, Antonina ;

Niro, Grazia ;

Mele, Alfonso .

HEPATOLOGY, 2007, 46 (04) :1312-1313

[20]

Gheorghe L, 2011, J GASTROINTEST LIVER, V20, P377

← 1 2 3 4 5 6 7 →